Page 43«..1020..42434445..5060..»

Turkish delegation seeks business partnership opportunities at biotech conference in Seoul – Aju Press

Posted: July 11, 2024 at 2:45 am

The delegation, comprised of the vice minister and representatives from four biotechnology firms, aimed to explore business opportunities, foster collaborations with Korean counterparts, and promote the Biotechnology Valley. This bioscience development and production infrastructure is located near Istanbul, a city that bridges Europe and Asia.

During the opening event, Vice Minister Dnmez expressed his hopes for stronger ties with Korea in the biotechnology sector.

"We would like to strengthen our relations with The Republic of Korea in the field of biotechnology and to establish concrete collaborations between our companies," he said. "We hope that this exhibition will be an important opportunity in this respect."

Caglar Kaharaman, a regional operations manager at Bio SB, a Turkish biotechnology firm specializing in the production and distribution of antibodies and detection systems for immunohistochemistry, highlighted the potential of Istanbul's Biotechnology Valley as a production hub for foreign companies.

"There is no other infrastructure that has better geographical advantages than our Biotechnology Valley," Kaharaman told Aju Press. He explained that setting up a base at the technology complex, which can host more than 400 manufacturers, allows firms to target markets in Europe, Asia, the Middle East, and beyond.

"We hope to collaborate with more Korean partners to create synergy, especially in the fields of healthcare and cosmetics. I strongly believe that the Biotechnology Valley will provide great business opportunities for Korean companies looking to expand into new markets," Kaharaman added.

Park Sae-jin swatchsjp@ajunews.com

More:
Turkish delegation seeks business partnership opportunities at biotech conference in Seoul - Aju Press

Posted in Biotechnology | Comments Off on Turkish delegation seeks business partnership opportunities at biotech conference in Seoul – Aju Press

When it comes to menopause, ‘it’s not all in your head,’ and Pittsburgh-based research is proving it – Bradford Era

Posted: July 11, 2024 at 2:45 am

PITTSBURGH (TNS) Julie Bonnett has been a personal trainer and group fitness instructor for 22 years, amassing a list of certifications too numerous to name and a client list that includes some high-profile, and beloved, Pittsburgh athletes.

By happenstance, she trains mostly women, which is convenient, as she has 53 years of experience as a female herself and just as much experience supporting other women, as a friend, sister and daughter.

But none of that fieldwork prepared her for what confronts women as they approach midlife.

When people talked about perimenopause and menopause, no one really knew the answers. Theyd just turn to their friends, who also didnt have any answers, Bonnett said. Its been such a taboo topic. People didnt talk about it, and people in my age range, most people didnt talk to their moms about it.

As a trainer, she heard these concerns from her clients, not only because they sought the slimmer, more toned physiques of their younger years, but because they often werent getting satisfying answers from their medical practitioners.

These gaps in knowledge are an unfortunate equalizer, as research shows they exist for both women and those who care for them, on multiple continents and across demographic groups, with 80% of women under 40 reporting no knowledge at all or just some knowledge of the menopausal transition, as shown in a 2022 study.

But the tide is turning, and some University of Pittsburgh researchers are at the helm, proving that menopause is far more than hormones and hot flashes, but a profound physiological change in womens bodies worthy of focus, funding and a cultural shift toward acknowledging this stage of life differently.

Taming tabooPitt researcher Rebecca Thurston is a nationally recognized leader in womens health, particularly at the intersection of menopause, cardiovascular disease and brain health.

She, too, hears pleas from midlife women to feel understood.

Oftentimes, women are running around to different providers to figure this out, and then they run into some providers who are relatively uninformed about the perimenopause and menopause transition, she said. In that context, they can feel dismissed about what theyre experiencing due to, potentially, these information gaps between the scientific literature around menopause and it not quite making it out into clinical dissemination.

That educational lag may also speak to a well-documented history of womens concerns being dismissed in society at large, particularly around a topic such as this one, which highlights both ageism and sexism, Thurston noted.

But as new generations of women reach midlife, those conventions are changing.

You see Millennials and Gen Z, theyre like, forget it. Were not going to hide this very normal and natural life transition, she said. I also think there are more women who are in positions of power and authority across multiple different industries, and theres increasing impatience in having this transition be something thats cloaked in silence, shame and taboo.

Because of cultural and scientific stumbling blocks to fuller discussions about menopause, the change was often generalized to merely mean the end of menstrual periods and the vague idea that hormones are involved.

Its true that menopause occurs when a woman has been without a period for 12 consecutive months, and perimenopause is recognized as the body gears up for that change, which is orchestrated by hormonal changes. Also true: Women often suffer in silence as they experience a plethora of other symptoms, such as brain fog, the redistribution of fat, and changes in sleep and mood.

Science is catching up. Researchers are beginning to explain not only the signs and symptoms associated with perimenopause and menopause the differences that women can sense in their bodies or that others might notice but underlying physiologic changes, many of which were either unrecognized or previously thought to be age-related rather than unique to women in this stage.

Science as validation

After noticing how many of her clients and friends were trying to reinvent the same wheel in their 40s and 50s, Bonnett pursued a Menopause Coaching Specialist certification through Girls Gone Strong, an organization dedicated to women-focused certification programs and coaching, as informed by professionals from Yale, Johns Hopkins and Baylor universities and more.

The experience further proved how specialized this set of knowledge is.

For a long time, Ive known all of the things that can happen if you dont eat enough protein, but I learned, for instance, that it can contribute to the brain fog women deal with, she said.

She also learned these symptoms can be subtle, and start much earlier than many think, in womens late-30s.

While its validating to hear that others are experiencing similar symptoms, the emerging science might lead to the most significant forms of support, and maybe a hint of uncomfortable reality.

Samar El Khoudary, a Pitt epidemiologist and pharmacist, researches cardiovascular disease in midlife women, and how menopause may contribute.

Through her research, and some performed by others, the scientific community now knows that women experience an increase in LDL (the so-called bad cholesterol), total cholesterol and the main fatty-protein carried by LDL during this stage of life, contributing to atherosclerosis and cardiovascular disease.

Further, HDL cholesterol, or good cholesterol, may change as women progress through menopause, rendering it less cardio-protective than previously thought.

When I go to my PCP, they say, At least your HDL is high, El Khoudary said. But me, researching this, I know that doesnt necessarily mean Im protected.

Her teams research also showed that, within two years of the final menstrual period, women begin to accumulate fat in their abdomens, a more dangerous area due to the inflammatory markers and the higher risk of metabolic disease associated with it.

Its interesting because research shows that women gain weight with menopause, but the research also shows that gaining weight is an aging phenomena, she said. What is related to menopause is where we put the fat in our bodies.

That fat also deposits around the heart, shes discovered, where inflammatory markers, and increased cardiovascular risk, follows.

Further, its now understood that the carotid artery one of the bodys largest vessels, which brings fresh oxygen and nutrients to the brain increases in thickness and gets wider around menopause, making the artery less able to accommodate changes.

Thurstons research shows that women are having more hot flashes than they think as monitored by an innovative sweat gland-assessing device worn on the sternum and higher numbers of hot flashes are indicators of cardiovascular disease risk, while ones experienced overnight are indicators of poor brain health.

The last thing I want to do is scare women, but these hot flashes are telling us something, she said. The action item is to start being on top of your cardiovascular health, by knowing blood pressure and lipid numbers, monitoring insulin resistance, maintaining a heart-healthy diet and adhering to medical therapies.

Thurston sits on the advisory board for Astellas Pharma, the company that developed Veozah, an alternative to hormone replacement therapies for the treatment of hot flashes, approved by the FDA in May 2023.

And she completely agrees with newly published findings showing that hormone replacement therapy, for the relief of menopausal symptoms, isnt as dangerous as propounded in 2002, which stated that HRT was linked to an increased risk of blood clots, stroke and breast cancer.

As El Khoudary interacts with this body of research, she thinks of her mother.

When she was in this stage, we didnt know what she was dealing with, she said. She thought she was just having a hot flash, but never thought that could have implications for heart health.

El Khoudary believes research on the menopausal transition empowers women in ways not available to previous generations, even if some practitioners are still catching up.

When you go to your PCP, ask, I have heard this can happen to my lipids, can we check that? And thats really what the goal is, she said. Women should have informed discussions with their PCPs, so that conversations can lead to better checking, screening and making sure everything is going the way we want in that stage of their lives.

Menopause coaching specialists like Bonnett are available to reroute home-based lifestyle habits and refer to medical practitioners as needed. If those practitioners seem underprepared, Thurston recommends looking up The Menopause Society, a nonprofit that compiles a directory of menopause-trained providers.

But first, women are best served to listen to their bodies and their instincts.

Its not all in your head. If you think something is changing, it probably is, Thurston said. But while we tend to think about menopause and midlife aging as all doom and gloom, I will tell you that midlife can be a wonderful time for women.

Our job as providers is to help women harness the good, decrease the bad and sail through midlife, which can be a great time.

Read more:
When it comes to menopause, 'it's not all in your head,' and Pittsburgh-based research is proving it - Bradford Era

Posted in Hormone Replacement Therapy | Comments Off on When it comes to menopause, ‘it’s not all in your head,’ and Pittsburgh-based research is proving it – Bradford Era

Hormone Replacement Therapy Market: A Comprehensive Study Exploring with Bayer, Amgen, Novartis – openPR

Posted: July 11, 2024 at 2:45 am

Hormone Replacement Therapy Market

Identify the impact of external forces impacting the industry growth especially in foreign markets, government, policies and regulations, consumer incomes and spending habits, new products entering in the market and their impact on the various industry players' products.

Get Quick Access to Sample Pages Now @ https://www.htfmarketintelligence.com/sample-report/global-hormone-replacement-therapy-market?utm_source=Krati_OpenPR&utm_id=Krati

According to HTF Market Intelligence, the Hormone Replacement Therapy Market is Anticipated to grow at a CAGR of 6.9% from 2023 to 2030

Hormone Replacement Therapy Market Overview Hormone Replacement Therapy (HRT) is a medical treatment involving the administration of hormones to supplement or replace hormones that the body no longer produces in adequate amounts. It is primarily used to alleviate symptoms caused by hormonal deficiencies or imbalances, such as those experienced during menopause or andropause (male menopause). HRT can involve the administration of estrogen, progesterone, testosterone, or a combination of these hormones, depending on the specific needs of the individual. The goal of HRT is to relieve symptoms and improve quality of life by restoring hormonal balance. However, it is important to note that HRT carries potential risks and benefits, and its use should be carefully considered and monitored under medical supervision.

Market Drivers: Increasing frequency of hormonal imbalances and related conditions and the increasing number of postmenopausal women and awareness of the benefits of HRT increasing is driving the market growth.

Market Opportunities: General practice and in Custom-made therapies are prescribed based on genetic information and individual hormonal needs to maximize efficacy and minimize side effects.

Highlighted of Hormone Replacement Therapy Market Segments and Sub-Segment:

Hormone Replacement Therapy Market by Key Players: Pfizer Inc. (United States), AbbVie Inc. (United States), Novo Nordisk A/S (Denmark), Bayer AG (Germany), Merck & Co., Inc. (United States), Eli Lilly and Company (United States), Mylan N.V. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Amgen Inc. (United States), Novartis AG (Switzerland)

Hormone Replacement Therapy Market by Types: Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Replacement, Others

Hormone Replacement Therapy Market by End-User/Application: Growth Hormone Deficiency, Hypothyroidism, Menopause, Others

Get Instant Discount (10-30% off) at Hormone Replacement Therapy Market Report https://www.htfmarketintelligence.com/request-discount/global-hormone-replacement-therapy-market?utm_source=Krati_OpenPR&utm_id=Krati

The study is a source of reliable data on Market segments and sub-segments, Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological innovations Value chain, and investor analysis.

Interpretative Tools in the Market: The report integrates the entirely examined and evaluated information of the prominent players and their position in the market by methods for various descriptive tools. The methodical tools including SWOT analysis, Porter's five forces analysis, and investment return examination were used while breaking down the development of the key players performing in the market.

Key Growths in the Market: This section of the report incorporates the essential enhancements of the marker that contains assertions, coordinated efforts, R&D, new item dispatch, joint ventures, and associations of leading participants working in the market.

Key Points in the Market: The key features of this Hormone Replacement Therapy market report include production, production rate, revenue, price, cost, market share, capacity, capacity utilization rate, import/export, supply/demand, and gross margin. Key market dynamics plus market segments and sub-segments are covered.

Basic Questions Answered *who are the key market players in the Hormone Replacement Therapy Market? *What are the regional growth trends and the leading revenue-generating regions for the Hormone Replacement Therapy Market? *What are the major Segments by Types for Hormone Replacement Therapy *What are the major applications of Hormone Replacement Therapy *Which Hormone Replacement Therapy technologies will top the market in the next decade?

Examine Detailed Index of full Research Study at@: https://www.htfmarketintelligence.com/report/global-hormone-replacement-therapy-market

Table of Content Chapter One: Industry Overview Chapter Two: Major Segmentation (Classification, Application, etc.) Analysis Chapter Three: Production Market Analysis Chapter Four: Sales Market Analysis Chapter Five: Consumption Market Analysis Chapter Six: Production, Sales, and Consumption Market Comparison Analysis Chapter Seven: Major Manufacturer's Production and Sales Market Comparison Analysis Chapter Eight: Competition Analysis by Players Chapter Nine: Marketing Channel Analysis Chapter Ten: New Project Investment Feasibility Analysis Chapter Eleven: Manufacturing Cost Analysis Chapter Twelve: Industrial Chain, Sourcing Strategy, and Downstream Buyers

Buy the Full Research Report of Hormone Replacement Therapy Market@: https://www.htfmarketintelligence.com/buy-now?format=1&report=9985?utm_source=Krati_OpenPR&utm_id=Krati

Thanks for reading this article; you can also get individual chapter-wise sections or region-wise report versions like North America, LATAM, Europe, or Southeast Asia.

Nidhi Bhawsar (PR & Marketing Manager) HTF Market Intelligence Consulting Private Limited Phone: +15075562445 sales@htfmarketintelligence.com

About Author: HTF Market Intelligence Consulting is uniquely positioned to empower and inspire with research and consulting services to enable businesses with growth strategies, by offering services with extraordinary depth and breadth of thought leadership, research, tools, events, and experience that assist in decision-making.

This release was published on openPR.

Excerpt from:
Hormone Replacement Therapy Market: A Comprehensive Study Exploring with Bayer, Amgen, Novartis - openPR

Posted in Hormone Replacement Therapy | Comments Off on Hormone Replacement Therapy Market: A Comprehensive Study Exploring with Bayer, Amgen, Novartis – openPR

Moolenaar, Lawmakers Seek Answers After USDA Approves Chinese Genetically Engineered Soybeans – Select Committee on the CCP |

Posted: July 11, 2024 at 2:45 am

WASHINGTON D.C. --Chairman John Moolenaar (R-MI) of the House Select Committee on the Chinese Communist Party wrote to Secretary of Agriculture Tom Vilsack, inquiring why the U.S. Department of Agriculture greenlit a Chinese agricultural biotech company with close links to the Chinese government operating in the United States. The firm, Qi Biodesign, is a company that makes genetically engineered soybean seeds and was prioritized for USDA regulatory approval ahead of many American agricultural companies that currently face extensive delays.

Select Committee Members Neal Dunn (R-FL), Dusty Johnson (SD), Ashley Hinson (R-IA), Carlos Gimenez (R-FL), and Ben Cline (R-VA) joined the letter.

The lawmakers outline a host of concerns writing,Qi Biodesign and other PRC firms like it are directly supported by the PRC government with the explicit purpose to replicate and replace U.S. agriculture biotechnology. While the PRC is clear-eyed about its desire to never allow its agriculture industry to be reliant on foreign technology, it appears the USDA is approving PRC agriculture biotechnology without concern for U.S. supply chains or trade negotiations. USDAs clearance of Qi Biodesigns products undermines years of hard-nosed U.S. trade demands and could make U.S. farmers complicit in the PRCs desire to replace them.

In an era when the Chinese government forbids U.S. agricultural companies from operating in China, Chairman Moolenaar underscores how perplexing it is for USDA to extend these benefits to companies beholden to our chief adversary. Moreover, the decision to welcome a Chinese government-backed company that sells genetically engineered soybeans into the U.S. raises serious questions for American consumers that mistrust genetic engineering in China.

Government-backed actors from China also have a long history of stealing U.S. agricultural intellectual property, with some going as far as digging up seeds in U.S. farm fields to smuggle back to China. In light of the growing threat, Chairman Moolenaar requests the Secretary of Agriculture that immediately revisit the regulatory status review for Qi Biodesign and asks for a briefing to address the following questions:

Read the lawmakers' letter to the FDAHERE.

Read the original post:
Moolenaar, Lawmakers Seek Answers After USDA Approves Chinese Genetically Engineered Soybeans - Select Committee on the CCP |

Posted in Genetic Engineering | Comments Off on Moolenaar, Lawmakers Seek Answers After USDA Approves Chinese Genetically Engineered Soybeans – Select Committee on the CCP |

PoLoPo: The startup making egg protein from potatoes – ISRAEL21c

Posted: July 11, 2024 at 2:45 am

Over the past few years more and more companies have been hitting the food market with enticing offers of plant-based protein.

While this may be great news for vegans, plant-based proteins are incomplete because they are low in at least one essential amino acid. Animal-based proteins, meanwhile, contain all nine essential amino acids.

But what if we were to find a way to produce animal protein from plants?

Israel-based startup PoLoPo says it can produce protein from potatoes that is identical to protein derived from chicken eggs.

We use the plant molecular farming method, which is production of valuable metabolites and proteins [through the manipulation of the cell factory] in the plant, PoLoPo CEO and cofounder Maya Sapir-Mir tells ISRAEL21c.

We teach the plant to generate properties that originate in a completely different biological source, she adds.

Essentially, molecular farming entails insertion of genes useful for food production, through genetic engineering, into host plants that would otherwise not express those genes.

Regular potatoes already contain protein, but in very small quantities. Through molecular farming, PoLoPo specialists have created a new strain of potatoes.

The company claims this one-of-a-kind strain produces a lot more protein, and its molecular consistency is indistinguishable from egg protein, which is rich in ovalbumin a major protein component of egg white.

Our market product will be functional protein powder generated from our potato strain, explains Sapir-Mir.

PoLoPo was officially founded in 2022 by Sapir-Mir and her longtime research partner, Raya Liberman-Aloni.

The two plant scientists met 17 years ago during their doctoral studies at the Hebrew University of Jerusalem, specializing in metabolic engineering of plants.

We were researching the behavior of proteins in plants from citrus fruits to tomatoes, and even tobacco, explains Sapir-Mir.

We were always the odd ones out in academia, she laughs.

In 2017, the two women came up with a business idea to create a plant that produces animal protein for the food industry.

It took us some time to settle on potatoes, but once we got there, all the other pieces started falling into place.

PoLoPo is still in the research and development (R&D) phase. It has raised over $2 million so far in its first and only funding round, which allowed the company to weather the storm of October 7 relatively unscathed.

We have just opened our second funding round that hopefully will jumpstart us from the R&D phase to commercial phase, says Sapir-Mir.

The company, which has six full-time employees and three part-time workers, hopes its product will hit the market by 2027.

Sapir-Mir admits, however, the company will not be able to operate commercially in Israel or Europe due to strict regulations applied on GMO (genetically modified organisms) products.

The plan is to first enter the market in the United States. Weve already applied for a USDA permit to grow our plants in the US, she explains.

She adds that in the future the restrictions on genetically modified food products in Israel and Europe will likely be eased because theres no food security without GMO.

The food industry utilizes egg protein, normally generated from egg whites, in very, very large quantities, explains Sapir-Mir.

Ovalbumin has a host of valuable and functional properties revered by the food industry.

If you were to take a random product off a supermarket shelf and look at the label, theres a good chance youd see egg protein among the ingredients, she says.

Sapir-Mir adds that egg protein is used commercially in sweets, meat products, baked goods and even plant-based milk.

Once our product becomes fully commercialized, scaleup will be very easy. And at full scale, we will have competitive pricing compared to other commercial egg proteins on the market, notes Sapir-Mir.

Our hope is that one day our product replaces egg protein entirely.

YOU CAN GET ISRAEL21c NEWS DELIVERED STRAIGHT TO YOUR INBOX.

Read more:
PoLoPo: The startup making egg protein from potatoes - ISRAEL21c

Posted in Genetic Engineering | Comments Off on PoLoPo: The startup making egg protein from potatoes – ISRAEL21c

Gene Synthesis Market to Lead by 16.14% of CAGR to Hit USD 9.38 Billion by 2033 – BioSpace

Posted: July 11, 2024 at 2:45 am

The global gene synthesis market size surpassed USD 2.10 billion in 2023 and is projected to reach approximately USD 9.38 billion by 2033, expanding at a CAGR of 16.14% from 2024 to 2033. The gene synthesis market is experiencing significant growth due to advancements is synthetic biology, increased demand for personalized medicine and growing applications in drug development and research.

Download a sample version of gene synthesis market report @ https://www.towardshealthcare.com/personalized-scope/5170

Key takeaways

Gene synthesis is a laboratory method for creating artificial genes. Instead of extracting DNA from a living organism, scientists use chemical processes to build DNA sequences from scratch. This allows for the creation of custom DNA sequences that can be used in research, medicine and biotechnology. The ability to design and produce specific genes opens up a wide range of possibilities, from studying genetic functions to developing new treatments for diseases.

The gene synthesis market refers to the industry involved in producing and selling synthetic genes and related services. This market includes companies that offer custom DNA synthesis, where researchers can order specific DNA sequences tailored to their needs. The market has been growing rapidly due to advancements in technology, which have made gene synthesis more efficient and affordable.

Gene synthesis market at a glance

The gene synthesis market has seen remarkable growth and is poised for significant expansion over the next decade. This impressive growth can be attributed to the increasing demand for gene therapy and personalized treatments, which are becoming pivotal in modern healthcare and research.

The gene synthesis market encompasses various segments based on methods, services, and applications. Among the methods, solid-phase synthesis held the largest market share in 2023. This technique is widely used due to its efficiency and reliability in creating complex DNA sequences. In terms of services, antibody DNA synthesis dominated the market in 2023, reflecting the growing need for recombinant antibodies in research, diagnostics, and therapeutic applications. Meanwhile, viral DNA synthesis is expected to grow at the fastest rate during the forecast period, highlighting its importance in studying viral genetics and developing related therapies.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Advancements in Genomics and next-generation Sequencing (NGS) to act as a Driver

Advancements in genomics and next-generation sequencing (NGS) are major drivers for the gene synthesis market. These cutting-edge technologies enable scientists to quickly and accurately identify genes associated with various diseases, paving the way for the development of targeted therapies. Gene synthesis is crucial in this process as it provides the DNA constructs necessary for these applications.

Next-generation sequencing has revolutionized the field of genomics by allowing the sequencing of entire genomes at an unprecedented speed and accuracy. This capability has led to significant breakthroughs in understanding genetic disorders, cancers, and other complex diseases. For instance, by identifying specific genetic mutations responsible for certain types of cancer, researchers can develop targeted therapies that specifically attack cancer cells without harming healthy ones.

A recent example of advancements in this area is the development of CRISPR-based therapies. CRISPR, a gene-editing technology, relies heavily on synthetic DNA sequences to guide the editing process. Companies like CRISPR Therapeutics and Editas Medicine are using gene synthesis to create precise DNA sequences that can edit genes associated with diseases such as sickle cell anemia and beta-thalassemia.

Rise of Gene Editing Technologies Like CRISPR to Promote the Markets Growth

The rise of gene editing technologies, particularly CRISPR, is a significant driver of the gene synthesis market. CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, allows scientists to make precise and efficient changes to the DNA of living organisms. This technology has opened new avenues for gene therapy, creating a surge in demand for synthetic DNA fragments used in these therapies.

CRISPR's ability to target specific genes with unprecedented accuracy makes it a powerful tool in medical research and treatment. For example, researchers can use CRISPR to correct genetic mutations that cause diseases such as cystic fibrosis or muscular dystrophy. By inserting, deleting, or altering segments of DNA, CRISPR can potentially cure genetic disorders at their source.

Customize this study as per your requirement @ https://www.towardshealthcare.com/customization/5170

Skilled Workforce Shortage to Hamper the Markets Growth

One significant restraint on the gene synthesis market is the shortage of a skilled workforce. Gene synthesis is a complex process that requires specialized knowledge and expertise to operate and maintain advanced equipment. This lack of skilled professionals can hinder the market's growth, particularly in emerging regions where educational and training facilities may be less developed.

Gene synthesis involves several sophisticated techniques, including DNA sequencing, oligonucleotide synthesis, and the use of bioinformatics tools. These processes require a deep understanding of molecular biology, genetics, and biochemistry.

For example, many emerging markets in Asia, Africa and Latin America are experiencing rapid growth in biotechnology and life sciences. However, these regions often face challenges in attracting and retaining skilled professionals.

A recent development highlighting this issue is the global push for educational programs focused on biotechnology and gene synthesis. In 2023, several universities in India and China launched specialized courses aimed at training students in advanced genetic engineering and synthetic biology. These programs are designed to bridge the skill gap and produce a new generation of scientists proficient in gene synthesis technologies.

Xenotransplantation, An Emerging Opportunity for the Gene Synthesis Market

Xenotransplantation, the process of transplanting organs from animals to humans, represents a groundbreaking opportunity for the gene synthesis market. This field aims to address the chronic shortage of human organs available for transplantation by using genetically engineered animal organs. Gene synthesis plays a crucial role in this endeavor by enabling the precise genetic modifications needed to reduce organ rejection and improve compatibility with human recipients.

One of the major challenges in xenotransplantation is the human immune system's tendency to reject animal organs. To overcome this, scientists are using gene synthesis to modify the donor animal's genetic makeup, making the organs more acceptable to the human immune system. This involves inserting specific genes into the animal's DNA to produce proteins that can suppress immune responses, thus reducing the likelihood of rejection.

For example, recent advancements have been made in genetically modifying pigs, which are considered the most suitable donor animals due to their organ size and physiological similarities to humans. In 2022, a significant breakthrough was achieved when a team of researchers at the University of Maryland successfully transplanted a genetically modified pig heart into a human patient.

North America to Sustain as a Leader for the Market

North America has been a dominant force in the gene synthesis market, largely due to its strong focus on research and development. The United States leads the region with significant investments in biotechnology and synthetic biology. The presence of major biotech firms and well-established research institutions further bolsters market growth. The rising prevalence of genetic disorders and robust government support for scientific advancements contribute to the region's market leadership.

Europe is another significant player in the gene synthesis market, with countries like Germany, the United Kingdom, and France at the forefront. The region benefits from a strong academic and industrial research base, alongside substantial funding from both government and private sectors. The European Union's initiatives to support biotechnology and synthetic biology research have facilitated market growth.

Asia Pacific on to Grow at a Rapid Rate

Asia Pacific is expected to witness the fastest growth in the gene synthesis market during the forecast period. Countries like China, Japan, South Korea, and India are leading this growth. The region's expansion is fueled by increasing investments in biotechnology and genetic research, along with a growing number of biotech startups. Government initiatives to promote scientific research and healthcare advancements are also playing a crucial role.

India is emerging as a significant contributor to the gene synthesis market. The Indian government has launched several initiatives to support the biotechnology sector, recognizing its potential for economic growth and healthcare improvements. For instance, the Department of Biotechnology (DBT) has been funding numerous research projects and startups focused on gene synthesis and related technologies.

By Method, the Solid-phase Synthesis Segment Held the Largest Share in 2023

Solid-phase synthesis is the leading method in gene synthesis, favored for its efficiency and versatility in creating complex peptide-based molecules. It simplifies the purification process, accelerates the production of peptide intermediates, and ensures uniform particle sizes. This method's straightforward equipment and minimal environmental impact make it cost-effective, facilitating large-scale peptide synthesis used in various biotechnological applications.

By Services, the Antibody DNA Synthesis Segment Dominated the Market in 2023

Antibody DNA synthesis dominates the service segment of the gene synthesis market due to advancements in recombinant monoclonal antibody (rAb) technology. It plays a crucial role in developing modified antibody molecules used extensively in research, diagnostics, and therapeutic interventions. By automating the production of synthetic DNA products, this service supports the creation of recombinant antibodies (rAbs), vital for biological and toxicological research, as well as targeted therapies for conditions like autoimmune diseases and cancer.

By Application, the Gene & Cell Therapy Segment Dominated the Market

Among applications, gene & cell therapy development holds the largest share in the gene synthesis market. This segment leverages gene synthesis to engineers and insert artificial genes into cells, revolutionizing personalized medicine. It enables the creation of tailored treatments based on individual genetic profiles, known as pharmacogenetic and pharmacogenomic data. This approach aims to enhance patient care by providing precise and effective therapies that address specific genetic conditions and improve overall health outcomes.

Browse More Insights of Towards Healthcare:

Recent developments

Top Companies in the Gene Synthesis Market:

Acquire our comprehensive analysis today @ https://www.towardshealthcare.com/price/5170

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Browse our Brand-New Journals:

https://www.towardspackaging.com

https://www.towardsautomotive.com

https://www.precedenceresearch.com

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Get Our Freshly Printed Chronicle:https://www.healthcarewebwire.com

View original post here:
Gene Synthesis Market to Lead by 16.14% of CAGR to Hit USD 9.38 Billion by 2033 - BioSpace

Posted in Genetic Engineering | Comments Off on Gene Synthesis Market to Lead by 16.14% of CAGR to Hit USD 9.38 Billion by 2033 – BioSpace

Opinion: You’ll soon be eating cloned meat without knowing it – SaskToday.ca

Posted: July 11, 2024 at 2:45 am

Cloned food is entering Canadian markets without mandatory labelling.

Imagine savouring a steak from a cloned animal or sipping milk from a cloned cow. Investigative journalism by Thomas Gerbet of the CBC has revealed that this could soon be a reality. However, many agricultural producer groups have not been directly consulted about this development.

Health Canadas recent round of consultations, conducted with minimal public awareness, suggests that these products may soon be available without consumers knowledge, as there will be no mandatory labelling. The absence of such information on Health Canadas website only adds to the opacity surrounding cloned products.

The consultation, which concluded on May 25th, focused on updating the Policy on Foods Derived from Cloned Animals by Somatic Cell Nuclear Transfer and Their Progeny. This update proposes that cloned products be exempt from pre-market evaluation under Part B, Title 28 of the Food and Drug Regulations. This approach differs from other nations like the United States, Japan, and New Zealand.

But what precisely is animal cloning? The process aims to create a genetic replica of an animal by replacing the nucleus of an unfertilized egg with that of a somatic cell from the donor animal, forming an embryo. This embryo is then implanted into a surrogate mothers uterus, where it develops to term.

Artificial insemination, a well-established industry practice, involves collecting sperm from a male and artificially introducing it into a females reproductive system to facilitate fertilization, preserving genetic variability. Cloning, however, produces genetically identical animals, eliminating this variability.

From a food safety perspective, cloned products do not pose a threat to human health. However, the social and moral acceptability of cloning remains in question. It is doubtful that consumers will unconditionally accept this technology, especially in the absence of labelling. For traditional producers, integrating cloned products into the market could also taint consumer perceptions across entire categories, particularly meat and dairy.

This situation mirrors the backlash against genetically modified salmon, which faced immediate retail rejection despite being deemed safe. Irrespective of the safety profile, it is crucial to explain the technology and ensure consumers comprehend the rationale and necessity for such practices, both for their benefit and that of the industry.

For the industry, the imperative to amend regulations is less evident. Cloning is an expensive process, and the argument that reduced production costs will translate into lower retail prices for consumers is tenuous at best.

Without mandatory labelling, offering consumers a truly informed choice becomes problematic. We have witnessed similar issues with genetic engineering and GMOs. Health Canada appears poised to embrace technological advancements impacting our agri-food sector without adequately considering consumer rights and preferences.

Quite shameful.

Dr. Sylvain Charlebois is senior director of the agri-food analytics lab and a professor in food distribution and policy at Dalhousie University.

Troy Media

Originally posted here:
Opinion: You'll soon be eating cloned meat without knowing it - SaskToday.ca

Posted in Genetic Engineering | Comments Off on Opinion: You’ll soon be eating cloned meat without knowing it – SaskToday.ca

Cloned meat on the menu? – Troy Media

Posted: July 11, 2024 at 2:45 am

Reading Time: 3 minutes

Cloned food is entering Canadian markets without mandatory labelling

Health Canadas recent round of consultations, conducted with minimal public awareness, suggests that these products may soon be available without consumers knowledge, as there will be no mandatory labelling. The absence of such information on Health Canadas website only adds to the opacity surrounding cloned products.

The consultation, which concluded on May 25th, focused on updating the Policy on Foods Derived from Cloned Animals by Somatic Cell Nuclear Transfer and Their Progeny. This update proposes that cloned products be exempt from pre-market evaluation under Part B, Title 28 of the Food and Drug Regulations. This approach differs from other nations like the United States, Japan, and New Zealand.

But what precisely is animal cloning? The process aims to create a genetic replica of an animal by replacing the nucleus of an unfertilized egg with that of a somatic cell from the donor animal, forming an embryo. This embryo is then implanted into a surrogate mothers uterus, where it develops to term.

Artificial insemination, a well-established industry practice, involves collecting sperm from a male and artificially introducing it into a females reproductive system to facilitate fertilization, preserving genetic variability. Cloning, however, produces genetically identical animals, eliminating this variability.

From a food safety perspective, cloned products do not pose a threat to human health. However, the social and moral acceptability of cloning remains in question. It is doubtful that consumers will unconditionally accept this technology, especially in the absence of labelling. For traditional producers, integrating cloned products into the market could also taint consumer perceptions across entire categories, particularly meat and dairy.

This situation mirrors the backlash against genetically modified salmon, which faced immediate retail rejection despite being deemed safe. Irrespective of the safety profile, it is crucial to explain the technology and ensure consumers comprehend the rationale and necessity for such practices, both for their benefit and that of the industry.

For the industry, the imperative to amend regulations is less evident. Cloning is an expensive process, and the argument that reduced production costs will translate into lower retail prices for consumers is tenuous at best.

Without mandatory labelling, offering consumers a truly informed choice becomes problematic. We have witnessed similar issues with genetic engineering and GMOs. Health Canada appears poised to embrace technological advancements impacting our agri-food sector without adequately considering consumer rights and preferences.

Quite shameful.

Dr. Sylvain Charlebois is senior director of the agri-food analytics lab and a professor in food distribution and policy at Dalhousie University.

For interview requests, click here.

The opinions expressed by our columnists and contributors are theirs alone and do not inherently or expressly reflect the views of our publication.

Troy Media Troy Media is an editorial content provider to media outlets and its own hosted community news outlets across Canada.

Read this article:
Cloned meat on the menu? - Troy Media

Posted in Genetic Engineering | Comments Off on Cloned meat on the menu? – Troy Media

Stem Cell Banking Market Growth and Innovation 2024: Business – openPR

Posted: July 11, 2024 at 2:45 am

Stem Cell Banking Market Trends Overview 2024-2031:

A new Report by Coherent Market Insights, titled "Stem Cell Banking Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the Stem Cell Banking market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.

This report has a complete table of contents, figures, tables, and charts, as well as insightful analysis. The Stem Cell Banking market has been growing significantly in recent years, driven by a number of key factors, such as increasing demand for its products, expanding customer base, and technological advancements. This report provides a comprehensive analysis of the Stem Cell Banking market, including market size, trends, drivers and constraints, Competitive Aspects, and prospects for future growth.

Get a Sample Copy of This Report @ https://www.coherentmarketinsights.com/insight/request-sample/1354

The purpose of the market research study is to thoroughly investigate the industry in order to gain knowledge of the industry and its economic potential. As a result, the client has a complete knowledge of the market and business from past, present, and prospective aspects enabling them to allocate resources and investing money wisely.

Scope of the Stem Cell Banking Market:

The Stem Cell Banking market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2021, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Major Players Operating in the Stem Cell Banking Market:

Stem Cyte Inc. CRYO-CELL INTERNATIONAL INC. ViaCord Cordlife Group Limited SmartCells Inc. LifeCell International Pvt. Ltd. Cryoviva Biotech Pvt. Ltd. Cryo Stemcell Reliance Life Sciences Transcell Biolife Pvt. Ltd. Cordlife Group Limited Covis Pharma CSG Bio

Stem Cell Banking Market Segments:

By Source Type: Umbilical Cord Stem Cell Cord Blood Cord Tissue Placenta Adult Stem Cell Embryonic Stem Cell

By Service Type: Collection and Transportation Processing Analysis Storage

By Application: Leukemia Diabetes Lymphoma Cerebral Palsy Thalassemia Others

Geographical Landscape of the Stem Cell Banking market:

The Stem Cell Banking Market report provides information about the market area, which is further subdivided into sub-regions and countries/regions. In addition to the market share in each country and sub-region, this chapter of this report also contains information on profit opportunities.

North America (United States, Canada, and Mexico) Europe (Germany, France, UK, Russia, Italy) Asia-Pacific (China, Japan, Korea, India, and Southeast Asia) Latin America (Brazil, Argentina, Colombia) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

This report offers actionable growth insights and an extensive study comprising secondary research, primary interviews with industry stakeholders, and competitors, validation, and triangulation with the Coherent Market Insights regional database. Experts have detailed primary records with the market players across the value chain in all regions and industry experts to obtain qualitative and quantitative insights.

Buy-Now and Get Up to 25% Discount @ https://www.coherentmarketinsights.com/insight/buy-now/1354

Trends and Opportunities of the Stem Cell Banking Market:

The Stem Cell Banking market has seen several trends in recent years, and understanding these trends is crucial to stay ahead of the competition. This report also presents several opportunities for players in the market. The increasing demand for Stem Cell Banking in various industries presents several growth opportunities for players in the market.

Key Benefits for Stakeholders:

The study includes a comprehensive analysis of current Stem Cell Banking Market trends, estimations, and market size dynamics from 2024 to 2031 in order to identify the most potential prospects.

The five forces study by Porter underlines the role of buyers and suppliers in aiding stakeholders in making profitable business decisions and expanding their supplier-buyer network.

In-depth research, as well as market size and segmentation, can assist you in identifying current Stem Cell Banking Market opportunities.

The largest countries in each area are mapped based on their market revenue contribution.

The Stem Cell Banking Market research report provides an in-depth analysis of the top competitors in the Stem Cell Banking Market.

Stem Cell Banking Market 2024 Key Insights:

Research and analyze the Market standing and future forecast associated with production, price structure, consumption, and historical knowledge.

The report understands the structure of Stem Cell Banking Market trade by distinctive its varied segments and sub-segments.

Market split the breakdown knowledge by company, products, end-user, and prime countries, Stem Cell Banking Market history knowledge from 2017 to 2024 and forecast to 2031.

Analysis of Stem Cell Banking Market regarding individual growth trends, future prospects, and their contribution to the overall Stem Cell Banking Market.

Stem Cell Banking Market 2024 report analyses competitive expansions like agreements, new product launches, and acquisitions.

Research report targets the key international Market players to characterize sales volume, revenue, growth potential, drivers, SWOT analysis, and development plans in coming years.

Reasons to buy:

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying Top Manufacturers.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.

Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/1354

'

Q.1 What are the main factors influencing the Stem Cell Banking market? Q.2 Which companies are the major sources in this industry? Q.3 What are the market's opportunities, risks, and general structure? Q.4 Which of the top Stem Cell Banking Market companies compare in terms of sales, revenue, and prices? Q.5 Which businesses serve as the Stem Cell Banking market's distributors, traders, and dealers? Q.6 How are market types and applications and deals, revenue, and value explored? Q.7 What does a business area's assessment of agreements, income, and value implicate?

Author Bio:

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.

(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

Contact Us: Mr. Shah Coherent Market Insights Pvt. Ltd, U.S.: +1-206-701-6702 U.K.: +44-020-8133-4027 AUS: +61-2-4786-0457 INDIA: +91-848-285-0837 Email: sales@coherentmarketinsights.com

:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.

See more here:
Stem Cell Banking Market Growth and Innovation 2024: Business - openPR

Posted in Stem Cell Research | Comments Off on Stem Cell Banking Market Growth and Innovation 2024: Business – openPR

Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy

Posted: July 11, 2024 at 2:44 am

TRX103 is designed to reset the immune system, improve clinical outcomes, and potentially cure patients suffering from autoimmune and inflammatory disorders TRX103 is designed to reset the immune system, improve clinical outcomes, and potentially cure patients suffering from autoimmune and inflammatory disorders

See the article here:
Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy

Posted in Global News Feed | Comments Off on Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy

Page 43«..1020..42434445..5060..»